Cefotaxime Other names: Cephotaxime

Chemical formula: C₁₆H₁₇N₅O₇S₂  Molecular mass: 455.465 g/mol  PubChem compound: 5742673

Therapeutic indications

Cefotaxime is indicated for:

Lyme borreliosis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Lyme disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Peri-operative prophylaxis in colorectal, gastrointestinal, prostatic, urogenital, gynaecological surgery

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Peri-operative prophylaxis in surgical procedures such as colorectal, gastrointestinal, prostatic, urogenital and gynaecological surgery in patients who have a definite risk of post-operative infections. Cefotaxime should be used in combination with another antibiotic that can provide anaerobic cover in the treatment of intra-abdominal infections. Cefotaxime should be used in combination with an aminoglycoside in the treatment of infections caused by Pseudomonas. Protection is best insured by achieving adequate local tissue concentrations at the time contamination is likely to occur. Administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infection.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infections of the lower respiratory tract

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Lower respiratory tract infection and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infections of genitourinary system

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Urinary tract infectious disease
Infectious disease of genitourinary system
and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gonorrhea

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Gonorrhea

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Infectious disease of abdomen and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute Meningitis in case of gram-negative microorganisms in combination with another suitable antibiotic.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Sepsis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Systemic infection and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Endocarditis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Endocarditis and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Endocarditis

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Endocarditis and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Sepsis

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Systemic infection and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Acute Meningitis in case of gram-negative microorganisms in combination with another suitable antibiotic.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Infectious disease of abdomen and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infections of genitourinary system

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Urinary tract infectious disease
Infectious disease of genitourinary system
and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infections of the lower respiratory tract

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Lower respiratory tract infection and additionally at least one of
Cefotaxime susceptible species
Cefotaxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cefotaxime is contraindicated in the following cases:

Hypersensitivity to cephalosporins, hypersensitivity to penicillin

at least one of
Cephalosporin allergy
Allergy to penicillin

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: CEFOTAXIME 1g Powder for solution for injection or infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈